Female Infertility Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major female infertility markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.
The female infertility market has been comprehensively analyzed in IMARC's new report titled "Female Infertility Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Female infertility refers to a medical condition in which a woman is unable to conceive after a year of regular, unprotected intercourse or carry a pregnancy to term. The disorder often does not present itself with specific symptoms, and most women suffering from infertility do not experience any noticeable signs. However, some possible indications may include irregular or absent menstrual cycles, abnormal bleeding, pain or discomfort during intercourse, hormonal imbalances leading to acne or excessive hair growth, recurrent miscarriages, symptoms related to conditions like endometriosis or polycystic ovary syndrome (PCOS), etc. The diagnosis of female infertility involves a comprehensive evaluation performed by a fertility specialist or reproductive endocrinologist. The process typically begins with a thorough medical history review, such as discussions about menstrual cycles, previous pregnancies, any underlying health conditions, etc. Various diagnostic procedures may include blood tests to assess hormone levels and ovarian function, imaging studies like pelvic ultrasound to evaluate the reproductive organs, and other tests to examine ovulation and egg quality. In addition to this, numerous assessments, such as hysterosalpingography and laparoscopy, may be conducted to check the fallopian tubes.
The increasing cases of polycystic ovary syndrome (PCOS), hypothalamic dysfunction, premature ovarian insufficiency (POI), etc., that can disrupt normal ovulation are primarily driving the female infertility market. In addition to this, the rising incidence of several associated risk factors, including uterine abnormalities, pelvic adhesions, fallopian tube blockages, genetic disorders, etc., is also creating a positive outlook for the market. Moreover, the escalating utilization of hormone therapy to treat hormonal imbalances as it aids in stimulating ovulation, enhancing follicle development, and supporting endometrial preparation for embryo implantation is acting as another significant growth-inducing factor. Apart from this, the shifting preferences towards in-vitro maturation (IVM) over traditional in-vitro fertilization (IVF) since IVM eliminates the need for ovarian stimulation, thereby reducing the likelihood of ovarian hyperstimulation syndrome and offering a less invasive approach to fertility treatment, are further bolstering the market growth. Additionally, the ongoing advancements in preimplantation genetic testing (PGT), such as the introduction of PGT-A (aneuploidy screening), which helps in identifying embryos with chromosomal abnormalities, thus improving the chances of successful implantation and lowering the risk of miscarriage, are expected to drive the female infertility market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the female infertility market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for female infertility and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the female infertility market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the female infertility market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the female infertility market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current female infertility marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the female infertility market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the female infertility market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the female infertility market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of female infertility across the seven major markets?
What is the number of prevalent cases (2018-2034) of female infertility by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of female infertility by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with female infertility across the seven major markets?
What is the size of the female infertility patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of female infertility?
What will be the growth rate of patients across the seven major markets?
Female Infertility: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for female infertility drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the female infertility market?
What are the key regulatory events related to the female infertility market?
What is the structure of clinical trial landscape by status related to the female infertility market?
What is the structure of clinical trial landscape by phase related to the female infertility market?
What is the structure of clinical trial landscape by route of administration related to the female infertility market?
The female infertility market has been comprehensively analyzed in IMARC's new report titled "Female Infertility Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Female infertility refers to a medical condition in which a woman is unable to conceive after a year of regular, unprotected intercourse or carry a pregnancy to term. The disorder often does not present itself with specific symptoms, and most women suffering from infertility do not experience any noticeable signs. However, some possible indications may include irregular or absent menstrual cycles, abnormal bleeding, pain or discomfort during intercourse, hormonal imbalances leading to acne or excessive hair growth, recurrent miscarriages, symptoms related to conditions like endometriosis or polycystic ovary syndrome (PCOS), etc. The diagnosis of female infertility involves a comprehensive evaluation performed by a fertility specialist or reproductive endocrinologist. The process typically begins with a thorough medical history review, such as discussions about menstrual cycles, previous pregnancies, any underlying health conditions, etc. Various diagnostic procedures may include blood tests to assess hormone levels and ovarian function, imaging studies like pelvic ultrasound to evaluate the reproductive organs, and other tests to examine ovulation and egg quality. In addition to this, numerous assessments, such as hysterosalpingography and laparoscopy, may be conducted to check the fallopian tubes.
The increasing cases of polycystic ovary syndrome (PCOS), hypothalamic dysfunction, premature ovarian insufficiency (POI), etc., that can disrupt normal ovulation are primarily driving the female infertility market. In addition to this, the rising incidence of several associated risk factors, including uterine abnormalities, pelvic adhesions, fallopian tube blockages, genetic disorders, etc., is also creating a positive outlook for the market. Moreover, the escalating utilization of hormone therapy to treat hormonal imbalances as it aids in stimulating ovulation, enhancing follicle development, and supporting endometrial preparation for embryo implantation is acting as another significant growth-inducing factor. Apart from this, the shifting preferences towards in-vitro maturation (IVM) over traditional in-vitro fertilization (IVF) since IVM eliminates the need for ovarian stimulation, thereby reducing the likelihood of ovarian hyperstimulation syndrome and offering a less invasive approach to fertility treatment, are further bolstering the market growth. Additionally, the ongoing advancements in preimplantation genetic testing (PGT), such as the introduction of PGT-A (aneuploidy screening), which helps in identifying embryos with chromosomal abnormalities, thus improving the chances of successful implantation and lowering the risk of miscarriage, are expected to drive the female infertility market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the female infertility market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for female infertility and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the female infertility market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the female infertility market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the female infertility market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current female infertility marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the female infertility market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the female infertility market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the female infertility market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of female infertility across the seven major markets?
What is the number of prevalent cases (2018-2034) of female infertility by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of female infertility by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with female infertility across the seven major markets?
What is the size of the female infertility patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of female infertility?
What will be the growth rate of patients across the seven major markets?
Female Infertility: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for female infertility drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the female infertility market?
What are the key regulatory events related to the female infertility market?
What is the structure of clinical trial landscape by status related to the female infertility market?
What is the structure of clinical trial landscape by phase related to the female infertility market?
What is the structure of clinical trial landscape by route of administration related to the female infertility market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FEMALE INFERTILITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FEMALE INFERTILITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FEMALE INFERTILITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 FEMALE INFERTILITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FEMALE INFERTILITY - UNMET NEEDS
10 FEMALE INFERTILITY - KEY ENDPOINTS OF TREATMENT
11 FEMALE INFERTILITY - MARKETED PRODUCTS
11.1 List of Female Infertility Marketed Drugs Across the Top 7 Markets
11.1.1 Menopur (Menotropin) - Ferring Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bravelle (Urofollitropin) - Ferring
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ovidrel (Choriogonadotropin alfa) - Merck Serono
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Gonal-F (Follitropin alfa) - Merck Serono
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Crinone 8 (Progesterone gel) - atalent
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 FEMALE INFERTILITY - PIPELINE DRUGS
12.1 List of Female Infertility Pipeline Drugs Across the Top 7 Markets
12.1.1 OXO001 - Oxolife
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FEMALE INFERTILITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FEMALE INFERTILITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FEMALE INFERTILITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Female Infertility - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Female Infertility - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Female Infertility - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Female Infertility - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Female Infertility - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Female Infertility - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Female Infertility - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Female Infertility - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Female Infertility - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Female Infertility - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Female Infertility - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Female Infertility - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Female Infertility - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Female Infertility - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Female Infertility - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Female Infertility - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Female Infertility - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Female Infertility - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Female Infertility - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Female Infertility - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Female Infertility - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Female Infertility - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Female Infertility - Access and Reimbursement Overview
16 FEMALE INFERTILITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FEMALE INFERTILITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FEMALE INFERTILITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FEMALE INFERTILITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FEMALE INFERTILITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FEMALE INFERTILITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 FEMALE INFERTILITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FEMALE INFERTILITY - UNMET NEEDS
10 FEMALE INFERTILITY - KEY ENDPOINTS OF TREATMENT
11 FEMALE INFERTILITY - MARKETED PRODUCTS
11.1 List of Female Infertility Marketed Drugs Across the Top 7 Markets
11.1.1 Menopur (Menotropin) - Ferring Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bravelle (Urofollitropin) - Ferring
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ovidrel (Choriogonadotropin alfa) - Merck Serono
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Gonal-F (Follitropin alfa) - Merck Serono
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Crinone 8 (Progesterone gel) - atalent
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 FEMALE INFERTILITY - PIPELINE DRUGS
12.1 List of Female Infertility Pipeline Drugs Across the Top 7 Markets
12.1.1 OXO001 - Oxolife
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FEMALE INFERTILITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FEMALE INFERTILITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FEMALE INFERTILITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Female Infertility - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Female Infertility - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Female Infertility - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Female Infertility - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Female Infertility - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Female Infertility - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Female Infertility - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Female Infertility - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Female Infertility - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Female Infertility - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Female Infertility - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Female Infertility - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Female Infertility - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Female Infertility - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Female Infertility - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Female Infertility - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Female Infertility - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Female Infertility - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Female Infertility - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Female Infertility - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Female Infertility - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Female Infertility - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Female Infertility - Access and Reimbursement Overview
16 FEMALE INFERTILITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FEMALE INFERTILITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FEMALE INFERTILITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
